PMID- 28525878
OWN - NLM
STAT- MEDLINE
DCOM- 20180226
LR  - 20191008
IS  - 1879-6265 (Electronic)
IS  - 1879-6257 (Print)
IS  - 1879-6257 (Linking)
VI  - 23
DP  - 2017 Apr
TI  - Vaccine development for respiratory syncytial virus.
PG  - 107-112
LID - S1879-6257(16)30170-5 [pii]
LID - 10.1016/j.coviro.2017.03.012 [doi]
AB  - Respiratory syncytial virus (RSV) is an important and ubiquitous respiratory 
      pathogen for which no vaccine is available notwithstanding more than 50 years of 
      effort. It causes the most severe disease at the extremes of age and in settings 
      of immunodeficiency. Although RSV is susceptible to neutralizing antibody, it has 
      evolved multiple mechanisms of immune evasion allowing it to repeatedly infect 
      people despite relatively little genetic diversity. Recent breakthroughs in 
      determining the structure and antigenic content of the fusion (F) glycoprotein in 
      its metastable untriggered prefusion form (pre-F) and the stable rearranged 
      postfusion form (post-F) have yielded vaccine strategies that can induce potent 
      neutralizing antibody responses and effectively boost pre-existing neutralizing 
      activity. In parallel, novel live-attenuated and chimeric virus vaccine 
      candidates and other novel approaches to deliver vaccine antigens have been 
      developed. These events and activities have aroused optimism and a robust 
      pipeline of potential vaccine products that promise to provide a means to reduce 
      the public health burden of RSV infection.
CI  - Published by Elsevier B.V.
FAU - Graham, Barney S
AU  - Graham BS
AD  - Vaccine Research Center, National Institute of Allergy and Infectious Diseases, 
      National Institutes of Health, Bethesda, MD 20892, United States. Electronic 
      address: bgraham@nih.gov.
LA  - eng
GR  - ZIA AI005129-01/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20170516
PL  - Netherlands
TA  - Curr Opin Virol
JT  - Current opinion in virology
JID - 101560941
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Antibodies, Viral)
RN  - 0 (F protein, human respiratory syncytial virus)
RN  - 0 (Respiratory Syncytial Virus Vaccines)
RN  - 0 (Vaccines, Attenuated)
RN  - 0 (Vaccines, Synthetic)
RN  - 0 (Viral Fusion Proteins)
SB  - IM
MH  - Antibodies, Neutralizing/blood
MH  - Antibodies, Viral/blood
MH  - Drug Discovery/*trends
MH  - Humans
MH  - Respiratory Syncytial Virus Infections/*prevention & control
MH  - Respiratory Syncytial Virus Vaccines/administration & 
      dosage/*immunology/isolation & purification
MH  - Respiratory Syncytial Virus, Human/*immunology
MH  - Vaccines, Attenuated/administration & dosage/immunology/isolation & purification
MH  - Vaccines, Synthetic/administration & dosage/immunology/isolation & purification
MH  - Viral Fusion Proteins/*immunology
PMC - PMC5653266
MID - NIHMS867803
EDAT- 2017/05/20 06:00
MHDA- 2018/02/27 06:00
PMCR- 2018/05/16
CRDT- 2017/05/20 06:00
PHST- 2017/02/28 00:00 [received]
PHST- 2017/03/22 00:00 [accepted]
PHST- 2017/05/20 06:00 [pubmed]
PHST- 2018/02/27 06:00 [medline]
PHST- 2017/05/20 06:00 [entrez]
PHST- 2018/05/16 00:00 [pmc-release]
AID - S1879-6257(16)30170-5 [pii]
AID - 10.1016/j.coviro.2017.03.012 [doi]
PST - ppublish
SO  - Curr Opin Virol. 2017 Apr;23:107-112. doi: 10.1016/j.coviro.2017.03.012. Epub 
      2017 May 16.